Takeda Pharmaceutical Co Ltd (NYSE:TAK)
$ 13.45 -0.11 (-0.81%) Market Cap: 42.99 Bil Enterprise Value: 70.33 Bil PE Ratio: 22.63 PB Ratio: 0.94 GF Score: 79/100

Takeda Pharmaceutical Co Ltd Wave 1 Pipeline Opportunity Call - Part 2 - R&D Team Follow Up Call Transcript

Apr 21, 2021 / 12:00AM GMT
Release Date Price: $16.92 (+0.48%)
Ayako Iwamuro
Takeda Pharmaceutical Company Limited - Manager of IR and Global Finance

(foreign language) Good morning. At this time, we would like to begin the event. I'll be moderating this session today from Takeda IR. My name is Iwamuro. Thank you for joining us. (Operator Instructions) Yes, we'd like to begin the session.

Before we start, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in our other SEC filings. Please also refer to the important notice on Page 2 of today's presentation.

Now I'd like to begin the event. First, maribavir, soticlestat, and Orexin presentation will be done by our Takeda's development team. We'll be using the presentation material that we provided the other day. I hope you will have it on hand.

We will begin with the presentation on maribavir. [Sano-san],

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot